Biosimilars: Exploring the History, Science, and Progress

Area of Science:

• Oncology
• Pharmacoeconomics
• Regulatory Science

Background:

• Biosimilars present significant opportunities to enhance healthcare access and patient outcomes.
• They also hold the potential to substantially reduce overall healthcare expenditures for cancer patients.

Observation:

• The study examines the evolution of biosimilars globally, including regulatory pathways in the US, Europe, Asia, and Canada.
• It incorporates patient and clinician perspectives on safety, immunogenicity, and bioequivalence, which are critical factors influencing biosimilar uptake.

Findings:

• Despite progress since the first approvals in Europe (2006) and the US (2015), persistent concerns regarding immunogenicity, comparability, and overall biosimilarity hinder patient and provider acceptance.
• Clinical safety, efficacy, and tolerability are paramount concerns for patients, prescribers, and clinicians.

Implications:

• Addressing safety and comparability concerns is crucial for increasing biosimilar utilization in cancer care.
• Overcoming these barriers can lead to broader access to effective treatments and substantial healthcare cost savings.
• Continued research and transparent communication are essential to build confidence in biosimilar therapies.